Vandana Singh - Benzinga

Vandana Singh

Benzinga Staff Writer

About Vandana Singh

Vandana Singh, MBA Finance is an Editor of the Benzinga Breaking News. Vandana has been covering the healthcare sector for over 10 years, including providing support services to renowned investment banks.

Articles by Vandana Singh

Sensodyne Maker Haleon Leverages Eye-Level Shelf Placement To Outpace Rivals-Report

Haleon gains US market share at Walmart and Target by securing eye-level shelf placement with aggressive promotional strategies.

Why Is Belite Bio Stock Soaring Friday?

Why Is Belite Bio Stock Soaring Friday?

Canaccord Genuity initiates Belite Bio (BLTE) with a Buy and $303 target on FDA Priority Review for tinlarebant.

Boston Scientific Recalls Spinal Cord Stimulator Leads Over Fracture Risk

Boston Scientific Recalls Spinal Cord Stimulator Leads Over Fracture Risk

Boston Scientific recalls Infinion CX SCS leads following 1,081 injury reports. Health authorities urge immediate return of unused inventory.

A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths

A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths

Novartis and Bristol Myers pause CAR-T autoimmune trials after patient deaths and severe side effects spark safety concerns.

Modular Medical Secures National PBM Contract For Pivot Insulin Pump

Modular Medical Secures National PBM Contract For Pivot Insulin Pump

Modular Medical secured a national PBM contract to expand access to its Pivot tubeless insulin patch pump for patients managing diabetes.

DaVita Reaches Preliminary Settlement Class Agreement Following Ransomware Attack

DaVita Reaches Preliminary Settlement Class Agreement Following Ransomware Attack

A federal court preliminarily approves a class action settlement for 2.3 million patients affected by the DaVita ransomware attack.

FDA Slams Fresenius Over Leaking Dialysis Bags, Warns of Potentially Life-Threatening Risk

FDA Slams Fresenius Over Leaking Dialysis Bags, Warns of Potentially Life-Threatening Risk

FDA warns Fresenius over Utah plant violations, citing leaking dialysis bags and visual inspection failures. Read the full compliance update.

Ionis Drug Wins FDA Approval as First Alexander Disease Treatment

Ionis Drug Wins FDA Approval as First Alexander Disease Treatment

FDA approves Zanvastro from Ionis Pharmaceuticals as the first disease-modifying treatment for rare Alexander disease.

Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial

Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial

Aptevo Therapeutics announced a 93% clinical benefit rate for mipletamig in frontline acute myeloid leukemia trial results.

Why Is HUTCHMED Stock Soaring Thursday?

Why Is HUTCHMED Stock Soaring Thursday?

HUTCHMED stock jumps on a $1.3B GSK deal for its cancer drug HMPL-A830. Learn the financial terms and key global rights split.

AbbVie Touts Positive Data For Multiple Myeloma Drug

AbbVie Touts Positive Data For Multiple Myeloma Drug

AbbVie reports positive Phase 3 results for etentamig, showing higher response rates and improved survival in multiple myeloma patients.

Climb Bio’s Kidney Disease Therapy Gets Support for Extended Dosing Schedule

Climb Bio’s Kidney Disease Therapy Gets Support for Extended Dosing Schedule

Climb Bio announced positive Phase 1 data for CLYM116 and outlined its strategy to advance the IgA nephropathy candidate into Phase 3.

Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion

Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion

Medicus Pharma partners with Pfizer to commercialize CD228V in a licensing deal worth over $1 billion plus royalties.

Better Cancer Therapy Than Keytruda? Summit Therapeutics Partner's Ivonescimab Outperforms in Lung Cancer Study

Better Cancer Therapy Than Keytruda? Summit Therapeutics Partner's Ivonescimab Outperforms in Lung Cancer Study

Summit Therapeutics' partner Akeso reported positive overall survival results for ivonescimab in a Phase 3 lung cancer clinical trial.

FDA Fast-Tracks Liquidia Drug for Painful Systemic Sclerosis Complication

FDA Fast-Tracks Liquidia Drug for Painful Systemic Sclerosis Complication

Liquidia stock rises after the FDA grants Fast Track status to YUTREPIA for treating Raynaud’s phenomenon in systemic sclerosis.

Ultragenyx Forced To Cut Costs After Disappointing Phase 3 Results

Ultragenyx Forced To Cut Costs After Disappointing Phase 3 Results

Ultragenyx reports Phase 3 Aspire study of apazunersen failed to meet primary endpoints, prompting plans for expense cuts.

EXCLUSIVE: Modular Medical Secures FDA Clearance for Pivot Software Upgrades

EXCLUSIVE: Modular Medical Secures FDA Clearance for Pivot Software Upgrades

Modular Medical receives FDA clearance for software enhancements to its Pivot insulin delivery system ahead of its planned Q4 launch.

uniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Says

uniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Says

uniQure seeks accelerated FDA approval for its Huntington's gene therapy, AMT-130. William Blair resumes coverage with a $73 fair price.

Fortrea Leverages Early Phase Strengths to Accelerate Market Expansion

Fortrea Leverages Early Phase Strengths to Accelerate Market Expansion

Fortrea acquires Worldwide Clinical Trials' Early Phase division for $45 million in cash to expand its clinical research network.

Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study

Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study

Can-Fite BioPharma reports longer survival in its Phase 3 liver cancer trial and raises $4 million through a warrant exercise.